These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21514066)

  • 1. Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate.
    Winkfield KM; Chen MH; Dosoretz DE; Salenius SA; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e345-50. PubMed ID: 21514066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses.
    Lee LN; Barnswell C; Torre T; Fearn P; Kattan M; Potters L
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):282-9. PubMed ID: 12023131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation.
    Zagars GK; Pollack A; Pettaway CA
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):517-23. PubMed ID: 9806509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection.
    Wattson DA; Chen MH; Moran BJ; Dosoretz DE; Braccioforte MH; Salenius SA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e773-9. PubMed ID: 22300573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of death from prostate cancer in men with Gleason score 3+4 prostate cancer treated using brachytherapy with or without a short course of androgen deprivation therapy.
    Yang DD; Chen MH; Wu J; Braccioforte MH; Moran BJ; D'Amico AV
    Urol Oncol; 2022 Jan; 40(1):6.e21-6.e27. PubMed ID: 34315661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate.
    Cross CK; Shultz D; Malkowicz SB; Huang WC; Whittington R; Tomaszewski JE; Renshaw AA; Richie JP; D'Amico AV
    J Clin Oncol; 2002 Jun; 20(12):2863-8. PubMed ID: 12065563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy.
    Dosoretz AM; Chen MH; Salenius SA; Ross RH; Dosoretz DE; Katin MJ; Mantz C; Nakfoor BM; D'Amico AV
    Cancer; 2010 Feb; 116(4):837-42. PubMed ID: 20052734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer.
    Beyer DC; Thomas T; Hilbe J; Swenson V
    Brachytherapy; 2003; 2(2):77-84. PubMed ID: 15062144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and treatment outcome of Hispanic men with prostate cancer following external beam radiotherapy.
    Rosser CJ; Kuban DA; Levy LB; Pettaway CA; Chichakli R; Kamat AM; Sanchez-Ortiz RF; Pisters LL
    J Urol; 2003 Nov; 170(5):1856-9. PubMed ID: 14532792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction.
    Nguyen PL; Chen MH; Beckman JA; Beard CJ; Martin NE; Choueiri TK; Hu JC; Hoffman KE; Dosoretz DE; Moran BJ; Salenius SA; Braccioforte MH; Kantoff PW; D'Amico AV; Ennis RD
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1411-6. PubMed ID: 21708431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke.
    Hayes JH; Chen MH; Moran BJ; Braccioforte MH; Dosoretz DE; Salenius S; Katin MJ; Ross R; Choueiri TK; D'Amico AV
    BJU Int; 2010 Oct; 106(7):979-85. PubMed ID: 20230380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of race on freedom from prostate-specific antigen failure in prostate cancer patients treated with definitive radiation therapy.
    Young CD; Lewis P; Weinberg V; Lee TT; Coleman CW; Roach M
    Semin Urol Oncol; 2000 May; 18(2):121-6. PubMed ID: 10875452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e209-15. PubMed ID: 23332383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer.
    Raldow AC; Zhang D; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
    JAMA Oncol; 2015 Jun; 1(3):334-40. PubMed ID: 26181182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA; Stock RG; Stone N
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
    Merrick GS; Butler WM; Galbreath RW; Lief JH
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
    Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
    JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.